Chelation Therapy of Iron Overload With Pyridoxal Isonicotinoyl Hydrazone

Launched by CASE WESTERN RESERVE UNIVERSITY · Oct 27, 1999

Keywords

ClinConnect Summary

BACKGROUND:

Iron overload in patients with refractory anemia may be the consequence of repeated blood transfusion, of excessive absorption of dietary iron, or of a combination of both. The body lacks any effective means for the excretion of excess iron and in patients with refractory anemia, an inexorable accumulation of iron contained in transfused red cells or absorbed from the diet eventually exceeds the body's capacity for safe storage. Without treatment, widespread iron-induced damage to the liver, heart, pancreas, and other organs is followed by an early death, most often the result ...

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Patients meeting any of the following health conditions and eligible for Chronic PIH Treatment
• • Non- transfusion-dependent patients with iron-loading anemias
• • Transfusion-dependent patients who have previously been well-chelated with chronic subcutaneous or intravenous desferrioxamine
• • Iron-loaded, transfusion-dependent patients
• • Ages: 18-75 years old
• Exclusion Criteria:
• • People who are not eligible for chronic PIH therapy and not meet the medical conditions listed in the Inclusion criteria
• • Ages: 17 years old or younger or 76 years old or older